DrugPatentWatch Database Preview

Aldesleukin - Biologic Drug Details

Email this page to a colleague

« Back to Dashboard

Summary for aldesleukin

Tradenames:	1
Patents:	183
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for aldesleukin
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aldesleukin

Recent Clinical Trials for aldesleukin

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Autotelicbio	Phase 1
University of Sao Paulo	Phase 3
Conselho Nacional de Desenvolvimento Científico e Tecnológico	Phase 3

See all aldesleukin clinical trials

Recent Litigation for aldesleukin

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Amgen Inc. v. Accord Healthcare, Inc.	2018-06-28

See all aldesleukin litigation

PTAB Litigation

Petitioner	Date
	2012-09-25

See all aldesleukin litigation

Pharmacology for aldesleukin

Ingredient-type	Interleukin-2
Physiological Effect	Increased Lymphocyte Activation Increased Lymphocyte Cell Production

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for aldesleukin Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for aldesleukin Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for aldesleukin Derived from Patent Text Search

These patents were identified by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Chiron	PROLEUKIN	aldesleukin	VIAL	103293	001	1992-05-05		Delta Pharmaceuticals, Inc. (Durham, NC)	2012-02-03	RX		search
Chiron	PROLEUKIN	aldesleukin	VIAL	103293	001	1992-05-05		Coraje, Inc. (San Francisco, CA)	2039-02-26	RX		search
Chiron	PROLEUKIN	aldesleukin	VIAL	103293	001	1992-05-05		SciClone Pharmaceuticals, Inc. (San Mateo, CA)	2039-02-26	RX		search
Chiron	PROLEUKIN	aldesleukin	VIAL	103293	001	1992-05-05		Merck & Co., Inc. (Rahway, NJ)	2020-01-28	RX		search
Chiron	PROLEUKIN	aldesleukin	VIAL	103293	001	1992-05-05		Resprotect GmbH (Dresden, DE)	2015-02-01	RX		search
Chiron	PROLEUKIN	aldesleukin	VIAL	103293	001	1992-05-05		OncoPharmaceutical, Inc. (Los Gatos, CA)	2020-10-03	RX		search

International Patents for aldesleukin

Country	Patent Number	Estimated Expiration
Singapore	172313
Japan	2015007060
China	1461207
European Patent Office	1357935
Japan	2020147601
South Korea	20160132496